['hiv-1-infection']
['b/f/taf', 'f/taf', 'dtg', 'dtg placebo', 'f/taf placebo', 'b/f/taf placebo']

        Key Inclusion Criteria:

          -  Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum
             time periods:

               -  ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse
                  transcriptase inhibitor (NRTI) resistance prior to the screening visit)

               -  ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the
                  screening visit)

          -  Documented plasma HIV-1 RNA < 50 copies/mL during treatment with DTG+F/TAF or
             DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the
             screening visit

          -  Plasma HIV-1 RNA levels < 50 copies/mL at screening visit

          -  Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the
             Cockcroft-Gault formula for creatinine clearance

          -  No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed
             virologic failure

          -  Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
             infection are permitted to enroll

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      